Clinical Trials · NCT04252612

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

WithdrawnEARLY_Phase 1Pramlintide (Prohibited)
Phase
EARLY_Phase 1
Recruitment status
Withdrawn
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Enrollment
0
Start date
Jan 2020
Locations
1 site, United States
Primary endpoint
Participant Compliance
View Pramlintide compound reference